Table 3 Summary table of baseline clinical characteristics and biomarker scores for the cohort used for whole-genome transcriptomic analysis
EBRT—Hypo.; 60 Gy, 20 fractions (n = 91) | EBRT—HDR boost; 37 Gy, 15 fractions with a 12.5–15 Gy HDR brachytherapy boost (n = 214) | EBRT—Conv.; 74 Gy, 37 fractions) (n = 127) | |
|---|---|---|---|
Age (years) – median (min, max) | 68 (51, 82) | 66 (46, 79) | 71 (53, 79) |
Missing | 1 | 1 | 1 |
PSA (ng/ml) – median (min, max) | 19.3 (1.9, 180.0) | 20.8 (3.6, 225.0) | 17.5 (1.8, 234.0) |
Missing | 5 | 5 | 1 |
ISUP grade ( n ) | |||
1 | 2 | 5 | 6 |
2 | 28 | 39 | 40 |
3 | 22 | 68 | 30 |
4 | 13 | 36 | 14 |
5 | 26 | 66 | 36 |
T stage ( n ) | |||
1 | 6 | 6 | 0 |
2 | 31 | 66 | 8 |
3 | 51 | 139 | 111 |
4 | 2 | 1 | 0 |
Missing | 1 | 2 | 8 |
Tumor (%) – median (min, max) | 50 (5, 95) | 65 (5, 100) | 60 (5, 100) |
ADT duration (months) – median (min, max) | 27 (2, 39) | 18 (3, 99) | 24 (3, 36) |
Missing | 0 | 4 | 2 |
CAPRA risk score (n) | |||
Low (0 – 2) | 0 | 0 | 2 |
Intermediate (3 – 5) | 17 | 25 | 22 |
High (6 – 10) | 74 | 189 | 103 |